- Home
- DRMA vs NDRA Comparison
DRMA vs NDRA Comparison
Compare DRMA & NDRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRMA
- NDRA
- Stock Information
- Founded
- DRMA 2014
- NDRA 2007
- Country
- DRMA United States
- NDRA United States
- Employees
- DRMA N/A
- NDRA N/A
- Industry
- DRMA Biotechnology: Pharmaceutical Preparations
- NDRA Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- DRMA Health Care
- NDRA Health Care
- Exchange
- DRMA Nasdaq
- NDRA Nasdaq
- Market Cap
- DRMA 3.6M
- NDRA 3.1M
- IPO Year
- DRMA 2021
- NDRA 2017
- Fundamental
- Price
- DRMA $5.99
- NDRA $4.77
- Analyst Decision
- DRMA Strong Buy
- NDRA Strong Buy
- Analyst Count
- DRMA 1
- NDRA 1
- Target Price
- DRMA $10.00
- NDRA $46.00
- AVG Volume (30 Days)
- DRMA 32.3K
- NDRA 29.8K
- Earning Date
- DRMA 11-12-2025
- NDRA 11-14-2025
- Dividend Yield
- DRMA N/A
- NDRA N/A
- EPS Growth
- DRMA N/A
- NDRA N/A
- EPS
- DRMA N/A
- NDRA N/A
- Revenue
- DRMA N/A
- NDRA N/A
- Revenue This Year
- DRMA N/A
- NDRA N/A
- Revenue Next Year
- DRMA N/A
- NDRA N/A
- P/E Ratio
- DRMA N/A
- NDRA N/A
- Revenue Growth
- DRMA N/A
- NDRA N/A
- 52 Week Low
- DRMA $5.04
- NDRA $2.90
- 52 Week High
- DRMA $24.90
- NDRA $22.68
- Technical
- Relative Strength Index (RSI)
- DRMA 54.71
- NDRA 54.49
- Support Level
- DRMA $5.27
- NDRA $4.00
- Resistance Level
- DRMA $5.74
- NDRA $5.28
- Average True Range (ATR)
- DRMA 0.40
- NDRA 0.33
- MACD
- DRMA 0.07
- NDRA 0.11
- Stochastic Oscillator
- DRMA 80.17
- NDRA 60.16
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
About NDRA ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI at the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.